The Antiallodynic Effects of Intrathecal Zaprinast in Rats with Chronic Constriction Injury of the Sciatic Nerve
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Zaprinast is an inhibitor of phosphodiesterase 5, 6 and 9. Phosphodiesterase inhibitors could produce anti-nociceptive effects by promoting the accumulation of cGMP. We hypothesized that intrathecal zaprinast could attenuate the allodynia induced by chronic constriction injury of the sciatic nerve in rat. Methods: Sprague-Dawley rats were prepared with four loose ligations of the left sciatic nerve just proximal to the trifurcation into the sural, peroneal and tibial nerve branches. Tactile allodynia was measured by applying von Frey filaments to the lesioned hindpaw. The thresholds for the withdrawal responses were assessed. Zaprinast (3−100㎍) was administered intrathecally by the direct lumbar puncture method to obtain the dose-response curve and the 50% effective dose (ED50). Measurements were taken before and 15, 30, 45, 60, 90, 120, and 180 min after the intrathecal doses of zaprinast. The side effects were also observed. Results: Intrathecal zaprinast resulted in a dose-dependent antiallodynic effect. The maximal effects occurred within 15−30 min and then they gradually decreased down to the baseline level over time in all the groups. There was a dose dependent increase in the magnitude and duration of the effect. The ED50 value was 17.4 ㎍ (95% confidence intervals; 14.7-20.5㎍). No severe motor weakness or sedation was observed in any of the rats. Conclusions: Intrathecally administered zaprinast produced a dose-dependent antiallodynic effect in the chronic constriction injury neuropathic pain model. These findings suggest that spinal phosphodiesterase 5, 6 and 9 may play an important role in the modulation of neuropathic pain.
Abstract
Background: Zaprinast is an inhibitor of phosphodiesterase 5, 6 and 9. Phosphodiesterase inhibitors could produce anti-nociceptive effects by promoting the accumulation of cGMP. We hypothesized that intrathecal zaprinast could attenuate the allodynia induced by chronic constriction injury of the sciatic nerve in rat. Methods: Sprague-Dawley rats were prepared with four loose ligations of the left sciatic nerve just proximal to the trifurcation into the sural, peroneal and tibial nerve branches. Tactile allodynia was measured by applying von Frey filaments to the lesioned hindpaw. The thresholds for the withdrawal responses were assessed. Zaprinast (3−100㎍) was administered intrathecally by the direct lumbar puncture method to obtain the dose-response curve and the 50% effective dose (ED50). Measurements were taken before and 15, 30, 45, 60, 90, 120, and 180 min after the intrathecal doses of zaprinast. The side effects were also observed. Results: Intrathecal zaprinast resulted in a dose-dependent antiallodynic effect. The maximal effects occurred within 15−30 min and then they gradually decreased down to the baseline level over time in all the groups. There was a dose dependent increase in the magnitude and duration of the effect. The ED50 value was 17.4 ㎍ (95% confidence intervals; 14.7-20.5㎍). No severe motor weakness or sedation was observed in any of the rats. Conclusions: Intrathecally administered zaprinast produced a dose-dependent antiallodynic effect in the chronic constriction injury neuropathic pain model. These findings suggest that spinal phosphodiesterase 5, 6 and 9 may play an important role in the modulation of neuropathic pain.
참고문헌 (19)
- Zimmermann M, "Pathobiology of neuropathic pain", Eur J Pharmacol, 429, pp.23~37 (2001)
- Attal N, "Further evidence for ‘pain-related’ behaviours in a model of unilateral peripheral mononeuropathy", Pain, 41, pp.235~251 (1990)
- Bennett GJ, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man", Pain, 33, pp.87~107 (1988)
- Kupers RC, "A time course analysis of the changes in spontaneous and evoked behaviour in a rat model of neuropathic pain", Pain, 50, pp.101~111 (1992)
- Jain NK, "Sildenafil- induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway", Brain Res, 909, pp.170~178 (2001)
- Patil CS, "Sildenafil induces hyperalgesia via activation of the NO-cGMP pathway in the rat neuropathic pain model", Inflammopharmacology, 14, pp.22~27 (2006)
- Hoheisel U, "The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones", Pain, 117, pp.358~367 (2005)
- Lucas KA, "Guanylyl cyclases and signaling by cyclic GMP", Pharmacol Rev, 52, pp.375~414 (2000)
- 박성근, "쥐의 척수강 내로 투여한 Phosphodiesterase 억제제인 Zaprinast의 포르말린 유발 통증 반응 및 혈역학에 대한 영향", Korean Journal of Anesthesiology, 48(6), pp.651~655 (2005), 대한마취과학회
- Xu JJ, "Intermittent lumbar puncture in rats: a novel method for the experimental study of opioid tolerance", Anesth Analg, 103, pp.714~720 (2006)
- Chaplan SR, "Quantitative assessment of tactile allodynia in the rat paw", J Neurosci Methods, 53, pp.55~63 (1994)
- Tallarida RJ, "Statistical analysis of drug-drug and site-site interactions with isobolograms", Life Sci, 45, pp.947~961 (1989)
- Beavo JA, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", Trends Pharmacol Sci, 11, pp.150~155 (1990)
- Amarante LH, "The kappa-opioid agonist (＋", −)-bremazocine elicits peripheral antinociception by activation of the L-arginine, cyclic GMP pathway, pp.Eur J Pharmacol, 2002[DOI]
- Uckert S, "Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future", Eur Urol, 50, pp.1194~1207 (2006)
- Moreland RB, "Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor", Trends Endocrinol Metab, 10, pp.97~104 (1999)
- Pyne NJ, "cGMP signal termination", Biochem Soc Trans, 24, pp.1019~1022 (1996)
- Sousa AM, "The dual effect of a nitric oxide donor in nociception", Brain Res, 897, pp.9~19 (2001)
- Tegeder I, "Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin- induced nociception in rats", Neurosci Lett, 332, pp.146~150 (2002)